Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
Status:
Completed
Trial end date:
2018-01-06
Target enrollment:
Participant gender:
Summary
The aim of this study is to test the hypothesis, that the order of application of Busulfan
(BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem
cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
Phase:
N/A
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborators:
University Hospital, Geneva University Hospital, Zürich